Demographic distributions of the patients and significant differences between the training and test datasets. by Kenta Ninomiya (9969368)

Significant clinical features and number of blood transfusions in cases and controls in three trimesters. by Shyamali Thilakarathne (21736055)

Genes and variant counts for pathways significantly associated with familial lymphoid cancer cases. by Sneha Ralli (16016296)

Multivariable logistic analysis showing significant indicators and their odds ratios of dengue confirmation in the health facility-based fever surveillance. by Jacqueline Kyungah Lim (10125351)

Characterization and outcomes of lymphoma cases based on stage (T-zone cases not included). by Heather Wilson-Robles (731578)

Plant growth, nodulation, and N content as affected by manipulating of GmNN1/FT2a. by Xinxin Li (281237)

Expression of <i>GmNN1/FT2a</i> in various tissues of soybean plants. by Xinxin Li (281237)

GmNN1/FT2a interacted with GmNYFA-C in the BiFC assay. by Xinxin Li (281237)

Indicators for competitive comparative advantage and their significance. by Linhan Shao (20978182)

Subjects:

Cases based on number of DG allocation units. by Zeeshan Memon Anjum (12413383)

Subjects:

Deterministic result of the base-case analysis. by Sudewi Mukaromah Khoirunnisa (15288505)

“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”

Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)

Base-case results based on evidence from randomized controlled trials (means and ranges). The comparator is no intervention. by Afschin Gandjour (342184)

Base-case results (deterministic analysis). by Robert Hodgson (2026294)

Base-case results: Probabilistic analysis. by Robert Hodgson (2026294)

Gene specific primers used for <i>GmNN1/FT2a</i> fine mapping. by Xinxin Li (281237)

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Top contributor of tissues of significant genes for AD. By ranking tissues based on their loadings in matrix <i>T</i>, we identified which tissues are the top contributors to signi... by Yan Yan (208529)

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”